Rossi, Marco http://orcid.org/0000-0002-2246-3730
Marzi, Federico
Natale, Mariarita
Porceddu, Aristotele
Tuccori, Marco
Lazzerini, Pietro Enea
Laghi-Pasini, Franco
Capecchi, Pier Leopoldo
Funding for this research was provided by:
Agenzia Italiana del Farmaco, Ministero della Salute (H56D15000370001)
Article History
Accepted: 3 February 2021
First Online: 8 April 2021
Declarations
:
: This study was supported by a grant from the Italian Medicines Agency, AIFA (no. H56D15000370001).
: Marco Rossi, Federico Marzi, Mariarita Natale, Aristotele Porceddu, Marco Tuccori, Pietro Enea Lazzerini, Franco Laghi-Pasini, and Pier Leopoldo Capecchi have no conflicts of interest that are directly relevant to the content of this article.
: The study has been approved by our institutional ethic committee on December 19, 2016 (reference number 10451/2016) and it has been performed in accordance with the ethical standards as laid down in the Declaration of Helsinki. Informed consent, including consent for publication, was obtained from all individual participants.
: All patients included in the database were anonymized by the use of alphanumeric codes assigned by the system.
: Consent for publication was obtained from all individual participants.
: The dataset generated and analyzed during the study is available from the corresponding author.
: All patients included in the database were anonymized by the use of alphanumeric codes assigned by the system.
: MR: conceptualization, methodology, software, formal analysis, writing—original draft. FM: investigation, validation. AP: investigation. MN: data curation, validation. MT: software. PEL: supervision, methodology, formal analysis. FLP: conceptualization, methodology, resources, funding acquisition. PLC: supervision, visualization, writing—review and editing. All authors read and approved the final manuscript.